ROCKWELL MEDICAL,INC. (NASDAQ:RMTI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item5.02 Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.

Effective as of March21, 2017, the Compensation Committee (the
Committee) of the Board of Directors of Rockwell Medical,Inc.
(the Company) made grants of performance-based restricted shares
under the Companys Amended and Restated 2007 Long Term Incentive
Plan (the Plan) to the Companys named executive officers as
follows:

The grants were approved by the Committee on March15, 2017. The
awarded shares fully vest upon the earliest to occur of any of
the following performance conditions: (a)reported net sales of
the Company in any four consecutive calendar quarters equals or
exceeds $100,000,000, (b)the market capitalization of the Company
is greater than $600,000,000 for ten consecutive trading days,
and (c)one year following the date the Centers for Medicare
Medicaid Services assign the Company transitional add on
reimbursement payment status for the drug product, Triferic. If
the vesting date occurs during a trading blackout period, vesting
will be delayed until the second day after the blackout trading
period is no longer in effect. The shares would also fully vest
immediately upon a change in control (as defined in the Plan).

If the grantees employment is terminated for any reason prior to
the shares becoming fully vested, the grantee forfeits the
shares, unless otherwise determined by the Committee. The shares
issued to the grantee may not be transferred by the grantee in
any manner prior to vesting. Grantees otherwise have all rights
of holders of common stock of the Company, including voting
rights and the right to receive dividends, if any.

The above description of the form of restricted stock agreement
does not purport to be a complete statement of the provisions
thereof. Such description is qualified in its entirety by
reference to the form of such agreement, which will be filed as
an exhibit to the Companys next Form10-Q.

About ROCKWELL MEDICAL, INC. (NASDAQ:RMTI)

Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its lead branded drug, Triferic is indicated for iron maintenance. Triferic is an iron compound that is delivered to hemodialysis patients through dialysate, replacing the iron loss that occurs during their dialysis treatment. Its generic drug, Calcitriol, is indicated for treating secondary hyperparathyroidism in dialysis patients. It manufactures, sells, delivers and distributes hemodialysis concentrates, along with a range of ancillary products.

ROCKWELL MEDICAL, INC. (NASDAQ:RMTI) Recent Trading Information

ROCKWELL MEDICAL, INC. (NASDAQ:RMTI) closed its last trading session up +0.28 at 6.33 with 331,607 shares trading hands.